NY-FGS-GLOBAL
21.11.2023 14:01:39 CET | Business Wire | Press release
FGS Global announced today that it has acquired Longview Communications and Public Affairs, bringing together two of the world’s leading communications and public affairs advisory firms. FGS will now be able to serve clients more extensively throughout North America, with a deeply experienced team across eight offices in the United States and three offices in Canada. FGS’s approximately 1,300 professionals around the world offer an integrated suite of capabilities, with deep local relationships and extensive knowledge across industries and geographies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231121931472/en/
Celebrating its 20th anniversary this year, Longview is the Canadian market leader, advising clients on corporate and financial communications, issues and crisis management, special situations, government relations, regulatory affairs and foreign direct investment approvals. Consistently ranked among the top 15 global PR advisors on M&A and shareholder activism, Longview advises a wide range of leading Canadian companies, as well as numerous global companies operating across the country. Its team of over 30 professionals brings extensive experience and relationships at the highest levels of government, media and business, and provides the firm’s clients an integrated service offering across disciplines that is unmatched in Canada.
Winnie Lerner, FGS’s Chief Executive Officer, North America, said, “Longview is the go-to team on all mission critical issues for companies in Canada. The firm has an outstanding track record, deep client relationships, and values aligned with our own. Extending our reach into Canada broadens our geographic footprint and enhances our ability to deliver for our clients. We have known and respected Longview for a long time, have partnered successfully on many prior client assignments and are thrilled to welcome them to FGS.”
Josh Pekarsky, Founder and Managing Partner at Longview, said, “Longview has always been about doing great work for our clients. This transaction furthers that goal and provides an exceptional platform for the future. We have been impressed by the quality and thoughtfulness of what FGS is building and are delighted to become part of this leading global platform as we embark on this next chapter of our growth. Together with FGS, we are better equipped than ever to guide our clients through an increasingly complex world and a rapidly evolving stakeholder, financial, regulatory and political environment.”
Longview has been renamed FGS Longview and will continue to be led by Longview Partners Josh Pekarsky, Bruce Drysdale, Ian Hamilton and Hugh McFadyen. FGS Longview has offices in Toronto, Vancouver and Calgary, as well as team members in Ottawa, Winnipeg, Montreal and Victoria.
Andrew Cole, FGS’s Deputy Global Chief Executive Officer, added, “FGS was created to help leaders succeed in increasingly complex stakeholder ecosystems across industries and geographies. Clients want a strategic communications and advocacy partner who can advise and execute across the inter-connected financial, media, regulatory, and employee audiences in their home country and across the globe. We’re excited to partner with the Longview team and together help clients succeed in Canada and around the world.”
About Longview
Longview is Canada’s leading corporate communications and public affairs firm, with a seasoned team of professionals working together across disciplines to serve our clients’ interests. Our strategy is simple: do good work. Longview is top ranked in Canada, and the only Canadian firm consistently ranked among the top 15 PR advisors globally, on M&A transactions and shareholder activism. Longview serves clients from seven locations across Canada. The firm’s practice areas include Corporate & Financial Communications, Public Affairs, Special Situations and Design & Branding.
About FGS Global
FGS Global is a leading global strategic communications consultancy, with approximately 1,300 professionals around the world, advising clients in navigating complex situations and reputational challenges. FGS Global was formed from the combination of Finsbury, The Glover Park Group, Hering Schuppener and Sard Verbinnen to offer board-level and c-suite counsel in all aspects of strategic communications — including corporate reputation, crisis management, government affairs and is also the leading force in financial communications worldwide. The firm is backed by WPP Plc and KKR & Co. Inc.
FGS Global offers seamless and integrated support with offices in the following locations: Abu Dhabi, Amsterdam, Beijing, Berlin, Boston, Brussels, Chicago, Dubai, Dublin, Düsseldorf, Frankfurt, Hong Kong, Houston, Kingston, London, Los Angeles, Munich, Paris, Riyadh, San Francisco, Shanghai, Singapore, Tokyo, Washington, D.C., South Florida, and Zurich. Its headquarters is in New York.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231121931472/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom